Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 13/20 | 0.57 |
| ▸ | CYSLTR2 | Q9NS75 | 10/20 | 0.57 |
| ▸ | ABCC1 | P33527 | 4/20 | 0.48 |
| ▸ | ABCC2 | Q92887 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.48 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.48 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.48 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30530488 | 1.00 | CYSLTR1 (0.57) | CYSLTR1CYSLTR2ABCC1ABCC2MEN1 | |
| SCHEMBL919522 | 1.00 | CYSLTR1 (0.57) | CYSLTR1CYSLTR2ABCC1ABCC2MEN1 | |
| SCHEMBL13513030 | 0.93 | CYSLTR1 (0.59) | CYSLTR1CYSLTR2ABCC1ABCC2MEN1 | |
| SCHEMBL6969865 | 0.87 | CYSLTR2 (0.48) | CYSLTR1CYSLTR2ABCC1ABCC2MEN1 | |
| SCHEMBL6969863 | 0.87 | CYSLTR2 (0.48) | CYSLTR1CYSLTR2ABCC1ABCC2MEN1 | |
| SCHEMBL5819160 | 0.86 | CYSLTR1 (0.57) | CYSLTR1CYSLTR2ABCC1ABCC2MEN1 | |
| SCHEMBL8303662 | 0.84 | CYSLTR1 (0.55) | CYSLTR1CYSLTR2ABCC1ABCC2MEN1 | |
| SCHEMBL8303664 | 0.84 | CYSLTR1 (0.55) | CYSLTR1CYSLTR2ABCC1ABCC2MEN1 | |
| SCHEMBL14843400 | 0.84 | CYSLTR1 (0.53) | CYSLTR1CYSLTR2ABCC1ABCC2MEN1 | |
| SCHEMBL14843401 | 0.84 | CYSLTR1 (0.53) | CYSLTR1CYSLTR2ABCC1ABCC2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2094665-A2 | PREPARATION OF MONTELUKAST AND ITS SALTS | Dr. Reddy's Laboratories Ltd. (IN) | 2009-09-02 | — | — | EP | claimed |
| WO-2008058118-A2 | PREPARATION OF MONTELUKAST AND ITS SALTS | DR. REDDY'S LABORTORIES, LTD. (IN) | 2008-05-15 | — | — | WO | claimed |
| CN-112430177-A | Synthesis method of montelukast sodium intermediate | 凯特立斯（深圳）科技有限公司 | 2021-03-02 | — | — | CN | disclosed |
| EP-2736885-B1 | QUINOLINE-, QUINOXALINE OR BENZOTHIAZOLE BASED CYSTEINYL LEUKOTRIENE ANTAGONISTS (LTC4) | SUN PHARMA ADVANCED RES CO LTD (IN) | 2020-03-25 | — | — | EP | disclosed |
| US-9102665-B2 | Cysteinyl leukotriene antagonists | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2015-08-11 | — | — | US | disclosed |
| US-20140155596-A1 | CYSTEINYL LEUKOTRIENE ANTAGONISTS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2014-06-05 | — | — | US | disclosed |
| EP-2736885-A2 | CYSTEINYL LEUKOTRIENE ANTAGONISTS | Sun Pharma Advanced Research Company Ltd (IN) | 2014-06-04 | — | — | EP | disclosed |
| WO-2013051024-A2 | CYSTEINYL LEUKOTRIENE ANTAGONISTS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2013-04-11 | — | — | WO | disclosed |
| US-20110021560-A1 | Compositions And Methods For Regulating Chondrocyte Proliferation In Bone Disorders | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL | 2011-01-27 | — | — | US | disclosed |
| WO-2011005574-A2 | COMPOSITIONS AND METHODS FOR REGULATING CHONDROCYTE PROLIFERATION IN BONE DISORDERS | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2011-01-13 | — | — | WO | disclosed |
| EP-2150533-B1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE ETHENYLPHENYL ALCOHOLS | LONZA AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| US-5104882-A | Leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1992-04-14 | — | — | US | disclosed |
| EP-0469833-A1 | N-Benzyl-Indoles, processes for their preparation and pharmaceutical compositions containing them | LILLY INDUSTRIES LIMITED (GB) | 1992-02-05 | — | — | EP | disclosed |
| WO-1991017163-A1 | IMIDAZO (4,5-c) PYRIDINES WITH PAF ANTAGONIST ACTIVITY | PFIZER INC. (US) | 1991-11-14 | — | — | WO | disclosed |
| EP-0399818-A1 | Diarylstyrylquinoline diacids | MERCK FROSST CANADA INC. (CA) | 1990-11-28 | — | — | EP | disclosed |
| US-4883878-A | REACTION OF QUINOLINE ALDEHYDE WITH AMIDE OR ESTER SUBSTITUTED MERCAPTAN | MERCK & CO. INC. (US) | 1989-11-28 | — | — | US | disclosed |
| EP-0328188-A2 | Process for unsymmetrical dithioacetals and dithioketals | MERCK & CO. INC. (US) | 1989-08-16 | — | — | EP | disclosed |
| US-4851409-A | LEUKOTRIENE ANTAGONIST, ANTIASTHMA, ANTIALLERGEN, ANTIINFLAMMATORY, CYTOPROTECTIVE | MERCK FROSST CANADA INC. (CA) | 1989-07-25 | — | — | US | disclosed |
| EP-0318093-A2 | Diarylquinoline diacids and their use as medicaments | MERCK FROSST CANADA INC. (CA) | 1989-05-31 | — | — | EP | disclosed |
| EP-0233763-A2 | 2-Substituted quinoline dioic acids | MERCK FROSST CANADA INC. (CA) | 1987-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155596-A1 | CYSTEINYL LEUKOTRIENE ANTAGONISTS | LTC4S, CYSLTR2, CYSLTR1 | CYSLTR1 3/4885CYSLTR2 2/4885ABCC1 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.